Canadian AIDS Treatment Information Exchange
CATIE envisions a future free of HIV and hepatitis C.
CATIE is Canada's source for accessible, evidence-based information about HIV and hepatitis C prevention, testing, care, treatment and support. CATIE strengthens the national response to HIV and hepatitis C by fostering collaboration and capacity among people living with HIV and/or hepatitis C and other affected populations, frontline service providers and researchers to reduce transmission and improve health and well-being.
CATIE is Canada's source for up-to-date, unbiased information about HIV and hepatitis C. We connect people living with HIV or hepatitis C, at-risk communities, healthcare providers and community organizations with the knowledge, resources and expertise to reduce transmission and improve quality of life.
Connect With the Tools You Need
The latest news about HIV and hepatitis C treatment and prevention in clear language
- Accurate online information
- Research updates
- Confidential inquiry line
Resources developed in partnership with organizations across Canada
- Free publications
- Program tools
- Case studies
Events for service providers to share approaches and lessons learned
- CATIE Forum
- Regional conferences
- Learning Institutes
Educational opportunities in person and online
- Training courses
Order a CATIE Brochure
This bilingual brochure provides a brief overview of CATIE's programs and services. Order a copy from the CATIE Ordering Centre.
Read more about CATIE's history and milestones.
How to Reach CATIE
CATIE (Canadian AIDS Treatment Information Exchange)
555 Richmond Street West, Suite 505
Toronto, Ontario M5V 3B1 Canada
Latest by Canadian AIDS Treatment Information Exchange
Montreal scientists found that 88% of cannabis users had an undetectable viral load. This suggests that a very large majority of cannabis users did not have problems adhering to antiretroviral therapy.
The scientists noted that daily ingestion of methadone provides an opportunity to supervise the consumption of HIV medications in places where methadone is dispensed.
A new study puts numbers to increasingly divergent trends in liver-related deaths vs. injection-related deaths in recent years, highlighting both the success of modern HCV treatment and the devastating effects of the opioid crisis.
"Providing HCV treatment alone while neglecting to concurrently address the social determinants of health will do little to improve the health outcomes of the majority of individuals with chronic HCV," the study authors wrote.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
"Placing more attention on meeting the sexual health and holistic wellness needs of gay men affected by sexualized substance use is critical," writes the associate director of Ontario's Gay Men's Sexual Health Alliance.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
Researchers hope that by interacting with the toll-like receptor protein TLR-7 an experimental drug can help increase the immune system's ability to sense and attack HIV and HIV-infected cells.
Researchers found that around 90% of participants who were switched to a dual drug regimen maintained a suppressed viral load over the course of the study.